Phosphoproteomic Characterization of Primary AML Samples and Relevance for Response Toward FLT3-inhibitors

Phosphoproteomic Characterization of Primary AML Samples and Relevance for Response Toward FLT3-inhibitors

Bibliographic Details
Main Authors:	David G. J. Cucchi, Carolien Van Alphen, Sonja Zweegman, Bo Van Kuijk, Zinia J. Kwidama, Adil al Hinai, Alexander A. Henneman, Jaco C. Knol, Sander R. Piersma, Thang V. Pham, Connie R. Jimenez, Jacqueline Cloos, Jeroen J. W. M. Janssen
Format:	Article
Language:	English
Published:	Wolters Kluwer 2021-07-01
Series:	HemaSphere
Online Access:	http://journals.lww.com/10.1097/HS9.0000000000000606

Similar Items

INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases
by: Robin Beekhof, et al.
Published: (2019-04-01)

INKA, an integrative data analysis pipeline for phosphoproteomic inference of active kinases
by: Robin Beekhof, et al.
Published: (2019-05-01)

Maturation State-Specific Alternative Splicing in <i>FLT3</i>-ITD and NPM1 Mutated AML
by: Anna Wojtuszkiewicz, et al.
Published: (2021-08-01)

The clinical and biological consequences of different FLT3 mutations in patients with AML
by: Mead, A. J.
Published: (2009)

Inhibition of FLT3 expression by green tea catechins in FLT3 mutated-AML cells.
by: Bui Thi Kim Ly, et al.
Published: (2013-01-01)

Overcoming Resistance to FLT3 Inhibitors in the Treatment of <i>FLT3</i>-Mutated AML
by: Stephen S.Y. Lam, et al.
Published: (2020-02-01)

Gene expression profiles associated with pediatric relapsed AML.
by: Costa Bachas, et al.
Published: (2015-01-01)

Analysis of Signalling Network Consequent to FLT3 in AML Patients
by: Chen, Hsiao-Wei Tina
Published: (2011)

Analysis of Signalling Network Consequent to FLT3 in AML Patients
by: Chen, Hsiao-Wei Tina
Published: (2011)

Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
by: Musa Yilmaz, et al.
Published: (2020-10-01)

Correction to: Outcomes with sequential FLT3-inhibitor-based therapies in patients with AML
by: Musa Yilmaz, et al.
Published: (2021-02-01)

CCL5 mediates target‐kinase independent resistance to FLT3 inhibitors in FLT3‐ITD‐positive AML
by: Silvia Waldeck, et al.
Published: (2020-04-01)

Dual inhibition of Fes and Flt3 tyrosine kinases potently inhibits Flt3-ITD+ AML cell growth.
by: Mark C Weir, et al.
Published: (2017-01-01)

Targeted Therapy of FLT3 in Treatment of AML—Current Status and Future Directions
by: Caroline Benedicte Nitter Engen, et al.
Published: (2014-12-01)

Therapeutic Vulnerabilities in <i>FLT3</i>-Mutant AML Unmasked by Palbociclib
by: Iris Z. Uras, et al.
Published: (2018-12-01)

Spontaneous Remission in an Older Patient with Relapsed FLT3 ITD Mutant AML
by: Pankit Vachhani, et al.
Published: (2016-01-01)

FLT3 Tyrosine Kinase Inhibitors for the Treatment of Fit and Unfit Patients with FLT3-Mutated AML: A Systematic Review
by: Michael Loschi, et al.
Published: (2021-05-01)

Phosphoproteomic Landscape of AML Cells Treated with the ATP-Competitive CK2 Inhibitor CX-4945
by: Mauro Rosales, et al.
Published: (2021-02-01)

FLT3 internal tandem duplication and FLT3-D835 mutation in 80 AML patients categorized into cytogenetic risk groups
by: Ewa Mały DEF, et al.
Published: (2010-10-01)

CXCR4 Inhibition Enhances Efficacy of FLT3 Inhibitors in FLT3-Mutated AML Augmented by Suppressed TGF-b Signaling
by: Bo-Reum Kim, et al.
Published: (2020-06-01)

Upfront Treatment of FLT3-Mutated AML: A Look Back at the RATIFY Trial and Beyond
by: Gina Keiffer, et al.
Published: (2020-12-01)

Aberrant Bone Homeostasis in AML Is Associated with Activated Oncogenic FLT3-Dependent Cytokine Networks
by: Isabel Bär, et al.
Published: (2020-11-01)

Hyper-methylation of the SOCS2 Promoter in AML: An Unexpected Association with the FLT3-ITD Mutation
by: McIntosh, Courtney
Published: (2009)

Hyper-methylation of the SOCS2 Promoter in AML: An Unexpected Association with the FLT3-ITD Mutation
by: McIntosh, Courtney
Published: (2009)

The Relationship Between FLT3 Mutations And Complete Remission Of AML Patients Referring To Shariati Hospital
by: Sakineh Abbasi, et al.
Published: (2013-09-01)

The Relationship Between FLT3 Mutations And Complete Remission Of AML Patients Referring To Shariati Hospital
by: Sakineh Abbasi, et al.
Published: (2013-09-01)

Uncovering the Genomic Landscape in Newly Diagnosed and Relapsed Pediatric Cytogenetically Normal FLT3‐ITD AML
by: Daelynn R. Buelow, et al.
Published: (2019-11-01)

Kinase Inhibitor Treatment of Patients with Advanced Cancer Results in High Tumor Drug Concentrations and in Specific Alterations of the Tumor Phosphoproteome
by: Mariette Labots, et al.
Published: (2020-02-01)

MRD Tailored Therapy in AML: What We Have Learned So Far
by: Lok Lam Ngai, et al.
Published: (2021-01-01)

Quantitative Phosphoproteomic Analysis Reveals Dendritic Cell- Specific STAT Signaling After α2-3–Linked Sialic Acid Ligand Binding
by: Rui-Jún Eveline Li, et al.
Published: (2021-04-01)

Petromurin C Induces Protective Autophagy and Apoptosis in FLT3-ITD-Positive AML: Synergy with Gilteritinib
by: You Na Ha, et al.
Published: (2020-01-01)

Chimeric antigen receptor (CAR)-modified T cells targeting FLT3 in acute myeloid leukemia (AML)
by: Jetani, Hardikkumar
Published: (2021)

Pre-Clinical Evaluation of the Proteasome Inhibitor Ixazomib Against Bortezomib-Resistant Leukemia Cells and Primary Acute Leukemia Cells
by: Margot S.F. Roeten, et al.
Published: (2021-03-01)

Combining Mass Spectrometry-Based Phosphoproteomics with a Network-Based Approach to Reveal FLT3-Dependent Mechanisms of Chemoresistance
by: Giusj Monia Pugliese, et al.
Published: (2021-04-01)

Integrating Phenotypic Search and Phosphoproteomic Profiling of Active Kinases for Optimization of Drug Mixtures for RCC Treatment
by: Judy R. van Beijnum, et al.
Published: (2020-09-01)

FLT3-ITD DNA allelic burden, but not mRNA levels, influences the biological characteristics of AML patients
by: Soare Dan S., et al.
Published: (2021-01-01)

Study of HOTAIR LncRNA in AML patients in context to FLT3-ITD and NPM1 mutations status
by: Mona Salah, et al.
Published: (2021-06-01)

AML/Normal Progenitor Balance Instead of Total Tumor Load (MRD) Accounts for Prognostic Impact of Flowcytometric Residual Disease in AML
by: Diana Hanekamp, et al.
Published: (2021-05-01)

The combination of CUDC-907 and gilteritinib shows promising in vitro and in vivo antileukemic activity against FLT3-ITD AML
by: Xinan Qiao, et al.
Published: (2021-06-01)

A PHOSPHOPROTEOMICS STUDY REVEALS PAK2 AS A THERAPEUTIC TARGET DURING CD44-INDUCED DIFFERENTIATION OF AML CELLS
by: Jalal Ahmed, Heba M.
Published: (2019)

Cannot write session to /tmp/vufind_sessions/sess_mijrptheoh3u6rdqb578bobd8q